

AD \_\_\_\_\_

Award Number: DAMD17-97-1-7313

TITLE: Regulation of Breast Carcinoma Progression by the Alpha-6  
Integrins

PRINCIPAL INVESTIGATOR: Leslie M. Shaw, Ph.D.  
**A. Mercurio**

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical  
Center, Incorporated  
Boston, Massachusetts 02215

REPORT DATE: September 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> September 2000	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Sep 99 - 31 Aug 00)	
<b>4. TITLE AND SUBTITLE</b> Regulation of Breast Carcinoma Progression by the Alpha-6 Integrins			<b>5. FUNDING NUMBERS</b> DAMD17-97-1-7313	
<b>6. AUTHOR(S)</b> Leslie M. Shaw, Ph.D. A. Mercurio			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Beth Israel Deaconess Medical Center, Incorporated Boston, Massachusetts 02215  <b>E-MAIL:</b> lshaw@caregroup.harvard.edu				
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b>  During the third year of this career development award, we have continued to make progress in determining the contribution of the $\alpha 6$ integrin receptors to breast carcinoma progression. In previous work we had established that the $\alpha 6 \beta 1$ receptor contributes to the growth and survival of breast carcinoma metastases. In addition, we had demonstrated that expression of the $\beta 4$ integrin subunit in breast carcinoma cell lines that lack this integrin subunit increases their invasive potential. Since submitting the initial proposal, we have demonstrated that the ability of the $\alpha 6 \beta 4$ integrin to promote carcinoma invasion involves its activation of phosphoinositide 3-OH kinase (PI3K) and the small GTP-binding protein Rac. We have also identified PKC-epsilon as a critical effector for invasion and we have determined that it contributes to cell motility through the regulation of lamellae organization and function. We have identified IRS-1 and IRS-2 as intermediate adapter proteins in the activation of PI3K by the $\alpha 6 \beta 4$ integrin and we have identified specific domains of the IRS proteins that are involved. We have also established that the $\alpha 6 \beta 4$ receptor can cooperate with the IGF-1R to activate the IRS proteins and promote IGF-1R signalling.				
<b>14. SUBJECT TERMS</b> Breast Cancer, Integrins, Invasion, IRS, PI3K				<b>15. NUMBER OF PAGES</b> 14
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## **Table of Contents**

<b>Cover</b>	<b>1</b>
<b>SF 298</b>	<b>2</b>
<b>Table of Contents</b>	<b>3</b>
<b>Introduction</b>	<b>4</b>
<b>Body</b>	<b>4</b>
<b>Key Research Accomplishments</b>	<b>7</b>
<b>Reportable Outcomes</b>	<b>7</b>
<b>Conclusions</b>	<b>7</b>
<b>References</b>	<b>8</b>
<b>Appendices</b>	<b>9</b>

## Introduction

Alterations in integrin expression and function during transformation are likely to have multiple consequences on tumor progression because of their adhesive and signaling properties (1,2). Our research has focused on the possible involvement of the  $\alpha 6$  integrins,  $\alpha 6\beta 1$  and  $\alpha 6\beta 4$ , receptors for the laminin family of matrix proteins, in breast cancer progression. This attention was triggered by the finding that high expression of the  $\alpha 6$  subunit in women with breast cancer correlated significantly with reduced survival times (3). In addition, a recent report also revealed a correlation between expression of the  $\beta 4$  subunit and poor prognosis (4). In order to take full advantage of the  $\alpha 6$  and  $\beta 4$  subunits as markers for predicting the prognosis of breast cancer, it is necessary to understand mechanistically how these integrins promote aggressive tumor behavior. Until this is established, the full potential of  $\alpha 6$  for diagnosis, or as a target for therapeutic development, will not be known. In previous work we had established that the  $\alpha 6\beta 1$  receptor contributes to the growth and survival of breast carcinoma metastases (5). In addition, we had demonstrated that de novo expression of the integrin  $\beta 4$  subunit in colon and breast carcinoma cell lines that lack this integrin subunit increases their invasive potential (6,7). The aims of this career development award were designed to investigate these  $\alpha 6$ -dependent functions in more molecular detail. In this regard, since submitting the initial proposal we have demonstrated that the ability of the  $\alpha 6\beta 4$  integrin to promote carcinoma invasion is related to its activation of phosphoinositide 3-OH kinase (PI3K) and the small GTP-binding protein Rac (7). We have recently identified the IRS proteins, IRS-1 and IRS-2 as intermediates in the activation of PI3K by the  $\alpha 6\beta 4$  integrin. The involvement of the IRS proteins in  $\alpha 6\beta 4$  signaling is intriguing given the importance of these proteins for signaling by other receptors, such as the IGF-1 and prolactin receptors, which have been implicated in breast carcinoma progression. In fact, we now have data to support a signaling cooperativity between the IGF-1 and  $\alpha 6\beta 4$  receptors that involves the IRS proteins. Finally, as reported in the previous annual report, we have identified Protein Kinase C-epsilon as a downstream effector of PI3K that is required for promoting carcinoma motility and invasion.

## Body

### Activation of PI3K by the $\alpha 6\beta 4$ integrin.

We previously demonstrated that the  $\alpha 6\beta 4$  integrin can promote carcinoma invasion through its ability to activate phosphoinositide 3-OH kinase (PI3K) and its downstream effectors, the small GTP-binding protein Rac and PKC-epsilon (7). The involvement of a PI3K-dependent signaling pathway in invasion is supported by other studies (8) and adds to previous data that have implicated PI3K in tumor promoting functions including transformation (9), cell survival (10, 11), anchorage-independent growth (12), and motility (13). Taken together, these findings support a central role for PI3K and its lipid products in carcinoma progression and highlight the need to investigate in more detail how this pathway is regulated. Although we have demonstrated that  $\alpha 6\beta 4$  can activate PI3K, a direct binding motif for the p85 regulatory subunit of PI3K is not present in the  $\beta 4$  cytoplasmic domain (14), suggesting that the activation of this lipid kinase is through intermediate signaling molecules. To identify these signaling intermediates, we sought to identify tyrosine phosphorylated proteins that associate with PI3K after ligation of the  $\alpha 6\beta 4$  receptor. As shown in Figure 1A, ligation of cells expressing the  $\alpha 6\beta 4$  receptor resulted in the association of PI3K with a 180kD phosphoprotein. These results suggest that the  $\alpha 6\beta 4$  integrin activates PI3K through a mechanism involving a 180kD intermediate.

To understand further the mechanism of  $\alpha 6\beta 4$  activation of PI3K, we identified the 180kD protein with which PI3K associates after  $\alpha 6\beta 4$  ligation. As shown in Fig. 1B, we have identified this phosphoprotein as IRS-2. IRS-2 belongs to the IRS family, a group of cytosolic adapter molecules that organize signaling complexes downstream of surface receptors, many of which have been implicated in mammary tumorigenesis (15,16). For example, the IRS proteins

are essential downstream signaling intermediates of the Insulin-like Growth Factor Receptor (IGF-1R) which has been linked to increased tumor recurrence and reduced survival of breast cancer patients (17,18). MDA-MB-435/mock and  $\beta 4$  transfectants were clustered with  $\alpha 6$ - or  $\beta 4$ -specific antibodies and cell extracts were immunoprecipitated with antibodies that recognize IRS-2. The immune complexes were immunoblotted with phosphotyrosine or p85 (PI3K) specific antibodies. Ligation of the  $\alpha 6\beta 4$  receptor, but not the  $\alpha 6\beta 1$  receptor, increased IRS-2 tyrosine phosphorylation (upper panel). More importantly, PI3K associated with IRS-2 after  $\alpha 6\beta 4$  ligation (lower panel). Addition of IGF-1 to the cells increased the level of IRS-2 phosphorylation and association with PI3K.

### **Mechanism of IRS-2 phosphorylation in response to $\alpha 6\beta 4$ ligation.**

The  $\alpha 6\beta 4$  receptor does not contain an intrinsic kinase domain and therefore it must activate an intermediate kinase to promote IRS-2 phosphorylation. The src family of non-receptor kinases has been shown previously to be capable of phosphorylating IRS-2. However, an inhibitor of the src kinases, PP2, did not prevent IRS-2 phosphorylation in response to  $\alpha 6\beta 4$  ligation (Fig. 2), although it did significantly diminish total levels of tyrosine phosphorylation in the cells. We are presently investigating alternative pathways for the  $\alpha 6\beta 4$ -dependent phosphorylation of IRS-2. These possibilities include members of the JAK kinase family of kinases and the IGF-1 receptor kinase. Identification of the kinase that is activated by  $\alpha 6\beta 4$  to promote IRS phosphorylation will provide a target for disrupting the  $\alpha 6\beta 4$ -dependent promotion of invasion and survival.

To investigate further the mechanism of IRS phosphorylation in response to  $\alpha 6\beta 4$  ligation, we have begun to identify the specific domains of IRS that are essential for  $\alpha 6\beta 4$ -dependent phosphorylation. The IRS proteins must be recruited to the plasma membrane to be functional. Several domains in the N-terminus of IRS are known to be required for their recruitment to the insulin and IGF-1 receptors. We have transiently transfected the MDA-MB-435/ $\beta 4$  transfectants with a series of IRS deletion mutants. As shown in Figure 3, the wildtype IRS and the  $\Delta$ SAIN deletion mutant were phosphorylated in response to  $\beta 4$  clustering. In contrast, the  $\Delta$ PH,  $\Delta$ PTB, and  $\Delta$ PH/PTB deletion mutants were not phosphorylated under the same conditions. These results indicate that the PH and PTB domains are essential for  $\alpha 6\beta 4$ -dependent phosphorylation. Using this information we will now use these minimal domains to identify the upstream proteins that interact with the IRS proteins in response to  $\alpha 6\beta 4$  ligation.

### **The $\alpha 6\beta 4$ integrin promotes phosphorylation of IRS-1 and IRS-2.**

IRS-2 belongs to a family of signaling adapters that includes IRS-1, IRS-2, IRS-3, and IRS-4 (15,16). To determine if other IRS homologs could also be activated by  $\alpha 6\beta 4$ , we examined the expression of the IRS family members in the MDA-MB-435 cells. As shown in Fig. 4, MDA-MB-435 cells expressed relatively low levels of IRS-1 (A) when compared with their level of IRS-2 expression (B). In contrast, another breast carcinoma cell line, T47D, expressed high levels of IRS-1 (Fig. 4A) and very low levels of IRS-2 (Fig. 4B). Neither of these cell lines expressed IRS-3 or IRS-4, which are known to be restricted in their tissue. The differences in the ability of the MDA-MB-435/mock and MDA-MB-435/ $\beta 4$  transfectants to promote IRS-2 phosphorylation is not due to a lack of IRS-2 expression in the mock transfectants because these subclones express equivalent levels of IRS-2 (Fig. 4B).

IRS-2 is tyrosine phosphorylated in response to  $\alpha 6\beta 4$  ligation in the MDA-MB-435 cells. Given that these cells express very low levels of IRS-1, T47D cells were used to examine the ability of  $\alpha 6\beta 4$  to promote IRS-1 phosphorylation. The  $\alpha 6\beta 4$  integrin was ligated with either  $\alpha 6$  or  $\beta 4$ -specific antibodies and cell extracts were immunoprecipitated with antibodies that recognize IRS-1 and immunoblotted with phosphotyrosine-specific antibodies. As shown in Fig. 4C, IRS-1 is tyrosine phosphorylated in response to  $\alpha 6\beta 4$  ligation.

### **The $\alpha 6\beta 4$ integrin and the IGF-1R cooperate to promote IRS-2 phosphorylation and PI3K activation.**

Growth factor/hormone and integrin receptors are both necessary to promote normal mammary epithelial and carcinoma functions. However, it is not clear how these receptors cooperate to promote signaling and to alter cellular function. To examine the influence of  $\alpha 6\beta 4$ -mediated IRS phosphorylation on IGF-1 signaling, we examined the ability of IGF-1 to promote tyrosine phosphorylation in the presence or absence of  $\alpha 6\beta 1$  or  $\alpha 6\beta 4$  ligation. As shown in Fig. 5, addition of IGF-1 to cells maintained in suspension resulted in a small increase in total cellular tyrosine phosphorylation. When  $\alpha 6\beta 1$  was ligated in the MDA-MB-435/mock transfectants, the stimulation of tyrosine phosphorylation by IGF-1 was not significantly increased. In contrast, ligation of the  $\alpha 6\beta 4$  integrin in the presence of IGF-1 in the MDA-MB-435/ $\beta 4$  transfectants resulted in a marked increase in the level of total cellular tyrosine phosphorylation. In addition, PI3K association with IRS-2 was significantly increased when  $\alpha 6\beta 4$  was ligated in the presence of IGF-1 in the MDA-MB-435/ $\beta 4$  cells (lower panel).

These results are important because the IGF-1R has been previously implicated in promoting breast carcinoma progression. The ability of the  $\alpha 6\beta 4$  integrin to promote IGF-1 signaling supports further the involvement of this integrin receptor in breast cancer.

### **Mutational analysis of the $\beta 4$ cytoplasmic domain.**

To investigate the mechanism by which the  $\alpha 6\beta 4$  receptor activates downstream signaling pathways to promote carcinoma invasion, we identified several tyrosine residues that are potential binding sites for downstream effectors. We have established stable transfectants of the MDA-MB-435 cells that express each of these  $\beta 4$  point mutants and we are presently characterizing these cell lines (Figure 6).

### Key Research Accomplishments:

- The  $\alpha 6 \beta 4$  integrin promotes PI3K activation through the IRS proteins IRS-1 and IRS-2.
- The src kinase is not involved in the  $\alpha 6 \beta 4$ -dependent phosphorylation of IRS-2.
- The PH and PTB domains of the IRS proteins are essential for  $\alpha 6 \beta 4$ -dependent phosphorylation.
- The  $\alpha 6 \beta 4$  integrin cooperates with the IGF-1 receptor to promote IRS phosphorylation and activation of PI3K.
- Construction of  $\beta 4$  tyrosine mutants and establishment of MDA-MB-435 cells expressing these mutant  $\beta 4$  subunits.

### Reportable Outcomes:

#### 1. Manuscripts

Chen, M.S., E.A.C. Almeida, A.-P.J. Huovila, Y. Takahashi, **L.M. Shaw**, A.M. Mercurio, and J.M. White. 1999. Evidence that different 'states' of the integrin  $\alpha 6 \beta 1$  interact with laminin and an ADAM. *J. Cell Biol.* 144:549-561.

Zrihan-Licht, S., Y. Fu, J. Settleman, K. Schinkmann, **L. Shaw**, I. Keydar, S. Avraham, and H. Avraham. 2000. RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion. *Oncogene* 19:1318-1328.

Guan, R.J., H.L. Ford, Y. Fu, **L.M. Shaw**, and A.B. Pardee. 2000. Overexpression of DRG 1 induces cell differentiation and suppresses colon cancer metastasis. *Cancer Res.* 60:749-755.

2. Submitted RO1 application (6/1/00) based on the work supported by this award.

3. Established new laboratory in the Department of Pathology at the Beth Israel Deaconess Medical Center.

### Conclusions

The overall goal of this career development award is to understand the contribution of the  $\alpha 6$  integrins to breast carcinoma progression. To date, we have made significant progress toward identifying  $\alpha 6 \beta 4$ -dependent signaling pathways that are involved in promoting breast carcinoma invasion. Activation of PI3K and the downstream effectors Rac and PKC-epsilon are essential for carcinoma invasion. We have identified the IRS proteins, IRS-1 and IRS-2, as intermediates in the activation of PI3K by the  $\alpha 6 \beta 4$  integrin. In addition, we have established a cooperative signaling mechanism for  $\alpha 6 \beta 4$  and the IGF-1R. We will continue to investigate the mechanism of  $\alpha 6 \beta 4$  signaling so that we can increase our understanding of how these pathways can be manipulated for therapeutic intervention in the future.

On a personal level, the work performed during this career development award has contributed to my establishment of an independent research program in the Department of Pathology at the Beth Israel Deaconess Medical Center.

## References

1. Hynes, R.O. 1992 Integrins: Versatility, modulation, and signaling in cell adhesion. *Cell* 69:11-25.
2. Juliano, R.L. and J.A. Varner. 1993. Adhesion molecules in cancer: the role of integrins. *Curr. Opin. Cell Biol.* 5:812-818.
3. Friedrichs, K., P. Ruiz, F. Franke, I. Gille, H.-J. Terpe, and B.A. Imhof. 1995. High expression level of  $\alpha 6$  integrin in human breast carcinoma is correlated with reduced survival. *Cancer Res.* 55:901-906.
4. Tagliabue, E., Ghirelli, C., Squicciarini, P., Aiello, P., Colnaghi, M.I., and S. Menard. Prognostic value of alpha 6 beta 4 integrin expression in breast carcinomas is affected by laminin production from tumor cells. *Clinical Cancer Res.* 4: 407-410, 1998.
5. Wewer, U.M., L.M. Shaw, R. Albrechtsen, and A.M. Mercurio. 1997. The integrin  $\alpha 6 \beta 1$  promotes the survival of metastatic human breast carcinoma cells in mice. *Amer. J. Path.* 151:1191-1198.
6. Chao, C., Lotz, M. M., Clarke, A. C., and Mercurio, A. M. A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells, *Cancer Research.* 56: 4811-9, 1996.
7. Shaw, L. M., Rabinovitz, I., Wang, H. H. F., Toker, A., and Mercurio, A. M. Activation of phosphoinositide 3-OH kinase by the Alpha-6-Beta-4 integrin promotes carcinoma invasion, *Cell.* 91: 949-960, 1997.
8. Keely, P. J., Westwick, J. K., Whitehead, I. P., Der, C. J., and Parise, L. V. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K, *Nature.* 390: 632-636, 1997.
9. Chang, H. W., Aoki, M., Fruman, D., Auger, K. R., Bellacosa, A., Tsichlis, P. N., Cantley, L. C., Roberts, T. M., and Vogt, P. K. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase, *Science.* 276: 1848-50, 1997.
10. Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., and Greenberg, M. E. Regulation of neuronal survival by the serine-threonine protein kinase Akt, *Science.* 275: 661-5, 1997.
11. Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N., and Hay, N. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal, *Genes & Development.* 11: 701-13, 1997.
12. Khwaja, A., Rodriguez-Viciana, P., Wennstrom, S., Warne, P. H., and Downward, J. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway, *EMBO Journal.* 16: 2783-93, 1997.
13. Derman, M. P., Toker, A., Hartwig, J. H., Spokes, K., Falck, J. R., Chen, C. S., Cantley, L. C., and Cantley, L. G. The lipid products of phosphoinositide 3-kinase increase cell motility through protein kinase C, *Journal of Biological Chemistry.* 272: 6465-6470, 1997.


14. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., and et al. SH2 domains recognize specific phosphopeptide sequences, *Cell*. 72: 767-78, 1993.
15. White, M. F., and Yenush, L. (1998) *Curr Top Microbiol Immunol* 228, 179-208
16. Yenush, L, and M.F. White. The IRS-signalling system during insulin and cytokine action. *Bioessays*, 19:491-500, 1997.
17. Turner, B. C., Haffty, B. G., Narayanan, L., Yuan, J., Havre, P. A., Gumbs, A. A. Kaplan, L., Burgaud, J. L., Carter, D., Baserga, R., and Glazer, P. M. (1997) *Cancer Res* 57(15), 3079-83
18. Resnik, J. L., Reichart, D. B., Huey, K., Webster, N. J., and Seely, B. L. (1998) *Cancer Res* 58(6), 1159-64

## **Appendices:**


1. Figures

## Figure 1

A.




B.




**Figure 1: Tyrosine phosphorylated proteins associated with PI3K after ligation with  $\alpha 6\beta 1$  and  $\alpha 6\beta 4$ .** The  $\alpha 6\beta 1$  and  $\alpha 6\beta 4$  integrins activate PI3K through distinct mechanisms. MDA-MB-435 transfectants were maintained in suspension or incubated with  $\alpha 6$ - or  $\beta 4$ -specific antibodies and allowed to adhere to anti-mouse IgG coated plates for 30 minutes. A) Aliquots of cell extracts that contained equivalent amounts of protein were immunoprecipitated with p85-specific antibodies and the immune complexes were immunoblotted with phosphotyrosine-specific (p-Tyr) antibodies. Ligation of  $\alpha 6\beta 1$  results in the association of PI3K with a 120kD phosphoprotein whereas ligation of  $\alpha 6\beta 4$  results in the association of PI3K with a 180 kD phosphoprotein. B) Aliquots of cell extracts that contained equivalent amounts of protein were immunoprecipitated with IRS-2-specific antibodies and the immune complexes were immunoblotted with phosphotyrosine-specific (p-Tyr) or PI3K specific (p85) antibodies. Mock, MDA-MB-435 cells transfected with vector alone;  $\alpha 6\beta 4$ , MDA-MB-435 cells transfected with the  $\beta 4$  subunit; S, cells maintained in suspension;  $\alpha 6$ , cells clustered with an  $\alpha 6$ -specific antibody;  $\beta 4$ , cells clustered with a  $\beta 4$ -specific antibody;  $\alpha 6+I$ , cells clustered with  $\alpha 6$ -specific antibodies in the presence of IGF-1.

**Figure 2**



**Figure 2: pp60-src is not involved in the phosphorylation of IRS-2 in response to  $\alpha\beta 4$  ligation.** MDA-MB-435/ $\beta 4$  transfectants were maintained in suspension (Lane 1) or incubated with  $\beta 4$ -specific antibodies and allowed to adhere to anti-mouse IgG coated plates for 30 minutes in the absence (Lane 2) or presence of the src kinase inhibitor PP2 (Lane 3) or the inactive inhibitor PP3 (Lane 4). Aliquots of cell extracts that contained equivalent amounts of protein were immunoprecipitated with IRS-2- or p-Tyr-specific antibodies and the immune complexes were immunoblotted with phosphotyrosine-specific (p-Tyr), PI3K-specific (p85), or IRS-2-specific antibodies. 1, cells maintained in suspension; 2, cells clustered with a  $\beta 4$ -specific antibody; 3, cells clustered with a  $\beta 4$ -specific antibody in the presence of PP2; 4, cells clustered with a  $\beta 4$ -specific antibody in the presence of PP3.


**Figure 3**




**Figure 3: Identification of the IRS domains that are essential for phosphorylation by the  $\alpha$ 6 $\beta$ 4 integrin.** MDA-MB-435/ $\beta$ 4 cells were transiently transfected with wild type IRS-1 or deletion mutants of IRS-1 that lack the PH, PTB, and SAIN domains. 24 hours after transfection, the cells were either incubated in suspension or clustered with  $\beta$ 4 specific antibodies. Cell extracts containing equivalent amounts of total protein were immunoprecipitated with either IRS-1- or IRS-2-specific antibodies and the immune complexes were resolved by SDS-PAGE and immunoblotted with phosphotyrosine-specific antibodies. The blots were subsequently stripped and re-probed with IRS-1 and IRS-2 antibodies to confirm expression. S, suspension;  $\beta$ 4, clustered with  $\beta$ 4-specific antibodies; V, vector alone;  $\Delta$ PH, IRS lacking the PH domain;  $\Delta$ PTB, IRS lacking the PTB domain;  $\Delta$ PH/PTB, IRS lacking both the PH and PTB domains;  $\Delta$ SAIN, IRS lacking the SAIN domain.

## Figure 4


### A. IRS-1 Expression



### B. IRS-2 Expression




### C.




**Figure 4: IRS-1 and IRS-2 expression in MDA-MB-435 and T47D cells.** A and B) Total cell lysates containing equivalent amounts of protein were resolved by SDS-PAGE and immunoblotted with antibodies specific for IRS-1 and IRS-2. C) T47D cells were maintained in suspension or incubated with  $\alpha 6$ - or  $\beta 4$ -specific antibodies and allowed to adhere to anti-mouse IgG coated plates for 30 minutes. Aliquots of cell extracts that contained equivalent amounts of protein were immunoprecipitated with IRS-1-specific antibodies and the immune complexes were immunoblotted with phosphotyrosine-specific (p-Tyr) antibodies. M, MDA-MB-435 cells transfected with vector alone;  $\beta 4$ , MDA-MB-435 cells transfected with the  $\beta 4$  subunit; 435, MDA-MB-435 cells; SUS, cells maintained in suspension;  $\alpha 6$ , cells clustered with an  $\alpha 6$ -specific antibody;  $\beta 4$ , cells clustered with a  $\beta 4$ -specific antibody.

## Figure 5



**Figure 6: Cooperative signaling between the  $\alpha 6\beta 4$  integrin and the IGF-1 receptor.** MDA-MB-435 transfectants were maintained in suspension or incubated with  $\alpha 6$ -specific antibodies and allowed to adhere to anti-mouse IgG coated plates for 30 minutes. IGF-1 (50 ng/ml) was added to the cells for the final 5 minutes of the clustering (+). Aliquots of cell extracts that contained equivalent amounts of protein were immunoprecipitated with phosphotyrosine-specific antibodies and the immune complexes were immunoblotted with either phosphotyrosine-specific (p-Tyr) or PI3K specific (p85) antibodies. Mock, MDA-MB-435 cells transfected with vector alone;  $\alpha 6\beta 4$ , MDA-MB-435 cells transfected with the  $\beta 4$  subunit; S, cells maintained in suspension;  $\alpha 6$ , cells clustered with an  $\alpha 6$ -specific antibody;  $\beta 4$ , cells clustered with a  $\beta 4$ -specific antibody; +, incubated with 50 ng/ml IGF-1.

**Figure 6**



**Figure 6:  $\beta 4$  Site-directed Mutagenesis.** A) Schematic of the  $\beta 4$  integrin subunit showing the tyrosine residues that we have mutated to phenylalanine. B) FACS analysis of surface expression of the  $\beta 4$  tyrosine mutants.